NAD+ is among the most cited molecules in the literature on aging and longevity. Present at roughly three grams in the adult body and involved in some 500 enzymatic reactions, it has become, within a few years, the center of gravity of a commercial sector estimated at several billion dollars. Between preclinical studies on animal models and the claims of supplement manufacturers, a considerable space remains to be mapped.
🧭 The narrative that spread across the web
NAD+ has established itself in the biohacking space as the "master molecule of aging." The dominant narrative can be summarized in a few lines: NAD+ levels collapse with age, that collapse is said to drive a cascade of cellular dysfunctions, and taking precursors in the form of dietary supplements or intravenous infusions would reverse this decline. Clinics offer infusions at several hundred euros per session, longevity podcasts treat it as essential, and influencers present the results of mouse studies as direct evidence of an anti-aging effect in humans.
This framing is appealing because it rests on a real foundation: the decline of NAD+ with age is documented, and preclinical studies are numerous. But the move from cellular mechanism to a promise of human longevity involves several leaps that the available data do not yet support. That is precisely where this analysis begins.
⚙️ What NAD+ does in every cell
NAD+ is a cofactor, meaning an auxiliary molecule without which certain enzymes cannot catalyze their reactions. In practice, it acts as an electron carrier: in the mitochondrial respiratory chain, it accepts electrons produced by the breakdown of carbohydrates and lipids, then transfers them to the mitochondria to produce ATP, the universal energy currency of the cell. Without this transfer, energy production stops.
But NAD+ is not limited to energy. It is the substrate for two enzyme families with distinct roles in cellular aging. Sirtuins use NAD+ to deacetylate proteins involved in DNA repair and the regulation of inflammation. PARPs, for their part, consume NAD+ to repair DNA strand breaks: each genetic lesion triggers a demand for NAD+ that the cell must meet. With age, DNA damage accumulates, PARPs become more active, and NAD+ reserves diminish. Think of NAD+ as a cellular energy budget that several departments compete for simultaneously: the more repair expenditure rises, the less remains for energy production and inflammatory regulation.
It is precisely this link, the age-related decline in NAD+ available to sirtuins and PARPs, that supplementation studies aim to correct. The final link in the chain remains contested: would restoring circulating NAD+ levels through external precursors produce the same protective effects as maintaining those levels naturally? The human answer to that question is what the following sections examine.
🔬 What human trials have measured
The systematic review published in the American Journal of Physiology in 2023 surveys the available clinical trials on NAD+ across various conditions: the authors conclude that while precursor supplementation does effectively raise circulating NAD+ levels, evidence of a significant clinical benefit remains limited and heterogeneous. In other words, raising the number in the blood is documented; raising the health of tissues is far less so.
The most cited study in the biohacking sphere is a randomized controlled trial published in Science in 2021 on 25 prediabetic women followed for 10 weeks. Oral NMN improved muscle insulin sensitivity compared to placebo, a real but narrowly defined metabolic signal. This population and this duration permit no extrapolation to a healthy adult seeking to slow aging.
In 2025, an observational study published in Nature Metabolism compared three precursors (NMN, nicotinamide riboside, and plain nicotinamide) on their effects on circulating NAD+ and the microbiome. The absorption profiles differ depending on the precursor and the route of administration, which means that earlier studies focused on a single precursor cannot be directly compared to one another.
On the intravenous side, a randomized controlled pilot trial published on medRxiv in 2024 evaluates the safety and efficacy of NAD+ infusions in healthy adults. The preliminary data document short-term effects on circulating levels but do not support conclusions about lasting clinical benefit, and the study had not yet undergone full peer review at the time of publication. Finally, a factorial randomized trial in The Lancet Neurology in 2026 examines NAD+ precursor supplementation combined with exercise in patients with Friedreich's ataxia, a progressive neurodegenerative disease: it is in these specific pathological contexts, where cellular deficit is documented, that human data are most advanced.
⚠️ What the narrative leaves out
The main blind spot in the human NAD+ literature comes down to a single variable: time. Most published clinical trials do not exceed 12 weeks. The preclinical studies on animal models that underpin the biohacking discourse cover entire lifespans in organisms with an accelerated metabolism. Transposing their results to chronic human supplementation over several years is an extrapolation that the authors themselves flag as unwarranted.
A further structural limitation is that the populations studied are small and targeted (prediabetic individuals, patients with rare diseases, frail older adults). The review published in Science Advances in 2024 on nicotinamide riboside in humans explicitly highlights the absence of trials in healthy adults with no pre-existing metabolic condition. In addition, the oncological question is rarely addressed in supplementation studies: NAD+ is a substrate for cell proliferation, and its role in tumor growth is the subject of a separate body of literature that is almost never cross-referenced with longevity studies in public-facing communications. Finally, the absence of regulatory standardization for commercial supplements means that the actual concentration and bioavailability of products on sale can vary significantly from the formulations used in trials.
The mechanism is real. The human horizon, however, remains to be built.
📌 What the literature supports
The available human trials converge on a modest, narrowly defined signal: supplementation with NAD+ precursors raises circulating levels, and metabolic effects have been observed in specific populations (prediabetic individuals, patients with mitochondrial diseases) over durations of less than 12 weeks.
What is established: NAD+ declines with age, oral precursors raise blood levels, and a benefit on muscle insulin sensitivity has been measured in a controlled trial. What remains contested: whether this metabolic benefit persists beyond 12 weeks, whether it applies to healthy adults, and whether the various precursors are equivalent to one another. What belongs to the narrative: the idea that chronic NAD+ supplementation reverses aging or extends human life expectancy, a claim for which no controlled clinical data are currently available.
What the absence reveals
What this literature reveals by its gaps is a structural asymmetry between the pace of science and the pace of the market. The cellular mechanisms of NAD+ were described over several decades of rigorous basic research. Human trials, by contrast, have only begun to accumulate over the past five years, over durations too short to answer the longevity questions that commercial discourse raises. Investors and manufacturers have moved ahead of researchers, something several teams flag explicitly in their publications under the term "hype."
The structural blind spot is not an absence of biological signal: it is an absence of long-term data in healthy populations. Taking the results of 10-week metabolic studies without taking their scope of application along with them would be like concluding from a stress test on a 500-meter stretch of road that a vehicle will hold up over 100,000 kilometers. What is at stake here is not the circulating NAD+ figure measured after supplementation. It is the question that no one has yet posed at scale: what happens to these markers, and to the health of the individuals, after two years of continuous supplementation in a 45-year-old adult with no pre-existing condition?
- 1NAD+ declines with age, but no human clinical trial published to date exceeds 12 weeks or measures an impact on life expectancy.
- 2The most cited randomized trial (oral NMN, 2021) enrolled 25 prediabetic women followed for 10 weeks: its results cannot be extrapolated to a healthy adult.
- 3The three main precursors (NMN, nicotinamide riboside, nicotinamide) show distinct absorption profiles, something that comparative studies published in 2025 are only beginning to document.
Sources for this analysis, ranked by level of evidence and by function in the argument., Evaluation of safety and effectiveness of NAD in different clinical conditions: a systematic review (2023) (REFERENCE, American Journal of Physiology, Endocrinology and Metabolism). Function: documents the state of clinical evidence on the efficacy and safety of NAD+ precursors across various conditions; serves as the foundation for the data section., The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans (2025) (REFERENCE, Nature Metabolism). Function: documents the distinct absorption profiles of the three main precursors; supports the central argument about study heterogeneity., What is really known about the effects of nicotinamide riboside supplementation in humans (2024) (REFERENCE, Science Advances). Function: synthesis of the human effects of nicotinamide riboside; explicitly highlights the absence of trials in healthy adults., Safety and efficacy of NAD+ precursor supplementation in Friedreich's ataxia (2026)00082-7/fulltext) (REFERENCE, The Lancet Neurology). Function: illustrates the specific pathological context in which human data are most advanced; contrasts with general longevity claims., Randomized, placebo, controlled pilot study evaluating NAD+ IV in healthy adults (2024) (REFERENCE, medRxiv, preprint without full peer review). Function: the only controlled trial available on intravenous infusions in healthy adults; used to flag the methodological limitations of the IV route., NPR, NAD infusions, supplements and longevity science (2026) (CONSENSUS, NPR). Function: documents the scientific community's alarm signal regarding the excessive marketing surrounding NAD+., PMC, NAD+ metabolism and roles in cellular processes during ageing (CONSENSUS, PubMed Central review). Function: reference foundation for the description of the cellular mechanism of NAD+ in the mechanism section., Progevita, NAD therapy: what it is and how it works (PERIPHERY, biohacking explainer). Function: illustrates the dominant narrative presenting NAD+ as a "symbol of modern biohacking"; serves as a reference point for the dominant narrative section.